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Abstract
B-1 lymphocytes are known to increase the metastatic potential of B16F10 melanoma cells
via the extracellular signal-regulated kinase (ERK) pathway. Since IL-10 is associated with
B-1 cells performance, we hypothesized that IL-10 could be implicated in the progression of
melanoma. In the present work, we found that the C57BL/6 mice, inoculated with B16F10
cells that were co-cultivated with B-1 lymphocytes from IL-10 knockout mice, developed
fewer metastatic nodules than the ones which were injected with the melanoma cells that
were cultivated in the presence of wild-type B-1 cells. The impairment of metastatic potential
of the B16F10 cells was correlated with low activation of the ERK signaling pathway, sup-
porting the idea that the production of IL-10 by B-1 cells influences the behavior of the
tumor. A microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is asso-
ciated with down-regulation of the genes that code for claudin-10, a protein that is involved
in cell-to-cell contact and that has been linked to lung adenocarcinoma. In order to deter-
mine the impact of claudin-10 in the cross-talk between B-1 lymphocytes and the B16F10
tumor cells, we took advantage of small interfering RNA. The silencing of claudin-10 gene in
B-1 lymphocytes inhibited activation of the ERK pathway and abrogated the B-1-induced
aggressive behavior of the B16F10 cells. Thus, our findings suggest that the axis IL-10/clau-
din-10 is a promising target for the development of therapeutic agents against aggressive
melanoma.
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Introduction
B-1 lymphocytes are part of the innate immune system and have distinct roles in inflamma-
tion, infection, and resistance to tumors. They constitute the central B-cell population in the
mice peritoneal and pleural cavities but rarely occur in spleen and lymph nodes [1, 2]. These
cells contribute toward the maintenance of natural IgM levels and are the major source of IL-
10, which is a regulatory cytokine involved in the downregulation of immune responses. In
response to the activation of the innate immunity, B-1 lymphocytes tend to increase both natu-
ral IgM and IL-10 levels, which are very important for the development of resistance to patho-
gens and also the modulation of several immune-mediated inflammatory responses [3, 4].
Despite an ever-growing interest in the role of B-1 cells in various immunological responses,
their participation in resistance or susceptibility to tumors has been neglected. Thus, the aim
of this study was to determine the involvement of B-1 cells in the behavior of B16F10 mela-
noma cells.
Using a heterotypic co-culture system, we demonstrated that upon contact with B-1 lym-
phocytes, the B16F10 melanoma cells increased the activation of the ERK signaling pathway
and up-regulated the expression of MMP-9, CXCR4, and MUC18, which in turn, led to
increased tumor growth and metastatic spreading [5–7]. We also showed that the functional
and phenotypic alterations that are observed in melanoma cells post contact with B-1 lympho-
cytes were dependent on the IL-10 production by the latter [6]. As B-1 lymphocytes produce
and utilize IL-10 as an autocrine growth factor [4], we hypothesized that this cytokine plays a
significant role in the interplay between B-1 and B16F10 cells.
In the current work, the differential gene expression between B-1 lymphocytes isolated
from the wild-type (B-1WT) or the IL-10 knockout (B-1IL-10-/-) mice was determined by the
microarray analysis. Among seven genes that displayed different expression patterns, claudin-
10, a component of tight junction strands, was chosen for functional analysis because it has
been reported to be associated with lung adenocarcinoma [8]. To this end, we used small inter-
fering RNA (siRNA) to silence the claudin-10 expression in B-1 lymphocytes and evaluated
the effects on the metabolism of the B16F10 cells. The silencing of claudin-10 expression in B-
1 lymphocytes impairs the ability of the cells to induce the ERK phosphorylation in the
B16F10 cells and to increase the aggressiveness of the tumor. Thus, our results demonstrate
that the axis IL-10/claudin-10 is a suitable target to control the behavior of melanoma cells.
Materials and methods
Mice
Female wild-type (WT), B cell-deficient (BKO) and IL-10 knockout (IL-10-/-) C57BL/6 mice,
6–8 weeks old, were obtained from Centro de Desenvolvimento de Modelos Experimentais
para Medicina e Biologia (CEDEME), Brazil. All mice were housed in a pathogen-free facility
and fed with autoclaved water and solid standard chow. This study was carried out in strict
accordance with the recommendations in the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health. This study was approved by the Ethics Committee of
the Universidade Federal de São Paulo, Brazil (Permit Number: 0799/08). All euthanasia was
performed using cervical dislocation method and all efforts were made to minimize suffering.
Cell culture
B16F10 melanoma cells were cultured in RPMI-1640 (Sigma, St Louis, MO, USA) containing
10% of fetal bovine serum (Cultilab, Campinas SP, Brazil) antibiotics and supplements. B-1
lymphocytes enriched fraction from wild-type (B-1WT) or IL-10-/- (B-1IL-10-/-) C57BL/6
Claudin-10 is involved in the pro-metastatic effect of B-1 lymphocytes on B16F10 melanoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0187333 November 16, 2017 2 / 13
Nacional de Desenvolvimento Cientı´fico e
Tecnolo´gico (CNPq; www.cnpq.br), grant numbers
472035/2011-8 and 308374/2016-9. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
mice were obtained by culture of five days of total peritoneal cells. As previously described [6],
free-floating cells correspond mostly to B-1 lymphocytes. The total peritoneal cells were
stained with anti-CD19, and anti-CD23 antibodies (BD Biosciences, USA) and the B-1 lym-
phocytes were separated by electronic cell sorting of CD19+CD23- cells (FACS Aria II cell
sorter, BD Biosciences, USA).
Purification of B-1 lymphocytes
Purified B-1 lymphocytes ex vivo were obtained from the peritoneal cavity of WT mice by suc-
cessive washed with RPMI medium. The cell suspension was labeled with anti-mouse CD19
APC and anti-mouse CD23 FITC (both from BD Biosciences, Mountain View, CA, USA) and
then submitted to electronic cell sorting using a FACSAria II cell sorter (BD Biosciences).
Finally, single B-1 lymphocytes (CD19+CD23-, pB-1WT) and other cells (non-B-1WT) were
collected separately.
Microarray sample preparation, Gene-chip hybridization and analysis
Trizol reagent (Invitrogen Corporation, Carlsbad, CA, USA) was used to isolate total RNA
from enriched cultures of B-1 WT or IL-10-/- lymphocytes. Three biological replicates of each
sample were used for the array hybridizations. The sample preparation, hybridization, and
microarray data analysis on GeneChip1 mouse genome 430 2.0 array (Affymetrix, Santa
Clara, CA, USA) were performed and analyzed as described [9]. Briefly, images were first
examined for visible defects using GeneChip 1 Operating Software (GCOS). Signal intensities
for each gene and data normalization were performed using RMA method (Robust Multi-
Array Analysis) [10] with RMA express software [11]. Differentially expressed genes were
identified using SAM (Significance Analysis of Microarray) with MultiExperiment Viewer
(MeV), software deployed by The Institute of Genomic Research–TIGR, Rockville, MD. The
criteria for selecting differentially expressed genes between B-1 lymphocytes from WT and IL-
10-/- mice was performed using fold change2 and false selection rate (FDR–false discovery
rate)4%. The microarray data are available at the ArrayExpress under protocol accession
E-MEXP-3973.
Transfection with siRNA
Three Stealth RNAi™ siRNA sequences were synthesized commercially by Invitrogen Life
Technologies Inc. (USA) with the help of tools available online (http://www.invitrogen.com).
Stealth RNAiTM siRNA1 (RNA)-AUCAUUAGUCCUCUACAUGCCUGGA (cldn-10 siRNA1,
primer number 148163E05), Stealth RNAiTM siRNA2 (RNA)-UCCAGGCAUGUAGAGGAC
UAAUGAU (cldn-10 siRNA2, primer number 148163E06), Stealth RNAiTM siRNA3 (RNA)-
UUUGCAUACAGGGAACAGCCUGUCA (cldn-10 siRNA3, primer number 148163E07) were
designed to target claudin-10 mRNA. The basic local alignment search tool (BLAST) was car-
ried out to verify the target of the three sequences. All sequences have the ability to suppress
any of six claudin-10 isoforms[12]. Stealth RNAi™ siRNA Negative Control (negative siRNA
12935–300, Ambion1/Life Technologies Corporation, CA, USA) was used to check nonspe-
cific cellular events caused by the introduction of the oligonucleotide into cells. For transfec-
tion, B16F10 cells or B-1 lymphocytes enriched culture were collected and seeded at 0.5x106
cells per well in a 12-well plate. Then, cells were transfected or not with 100 nM of claudin-10
siRNAi1, siRNAi2 or siRNAi3 or with negative control siRNA, according to the manufactur-
er’s protocol for siPORT™ NeoFX™ Transfection Agent (InvitrogenTM, Life Technology Inc.
CA, USA). The transfection efficiency of each Stealth RNAi™ siRNA sequence was confirmed
by flow cytometry using Silencer1 Cy™3 Labeled GAPDH (AM 4623, Ambion1/ Life
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Technologies Inc. CA, USA). The western blot analyses confirmed the silencing of claudin-10
expression.
Co-cultures of B16F10 cells and B-1 lymphocytes
As previously described 1x105 B16F10 cells were co-cultured with 1x106 B-1 lymphocytes in
6-well plate [6]. After 48 hours without changing the medium, non-adherent cells (B-1 lym-
phocytes) were removed, and adherent cells (B16F10 cells) were washed for three times with
phosphate-buffered saline (PBS) to remove all the remaining B-1 lymphocytes. B16F10 cells
were collected using trypsin (Cultilab, Brazil) for subsequent assays. To determine the purity
of B16F10 cells after co-cultures, they were incubated with CD11b and IgM antibodies (BD
Biosciences, USA) for flow cytometry analysis. The data acquisition was performed in a FACS-
Calibur using CELLQUEST software (BD Biosciences, USA), and data were analyzed using
FlowJo1 software (Tree Star Inc., USA).
Experimental metastasis assays
B16F10 melanoma cells recovered from culture were injected into the lateral tail vein of synge-
neic C57BL/6 mice (1x105cells/animal). After fourteen days, mice were euthanized, and the
number of lung tumor colonies was determined.
Total cellular protein extracts and western blot
Total protein extraction was performed as previously described [6]. Anti-phospho-ERK (E-4,
sc-7383), total ERK (K-23, sc-94) from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
anti-claudin-10 (38–8400) from Invitrogen (Invitrogen Corporation, CA), anti-β actin (Sigma,
St Louis, MO) or anti-GAPDH (AB9485) both from Abcam1 (Abcam1, Cambridge, USA)
were used as primary antibodies. Peroxidase-conjugated goat anti-mouse IgG (Sigma, St
Louis, MO) and anti-rabbit (BioRad, Hercules, CA, USA) were used as secondary antibodies.
The reactions were developed using a chemiluminescence ECL kit (Amersham Pharmacia,
Uppsala, Sweden). Bands were visualized using UVItec (UVItec Limited, Cambridge, UK) and
analyses were performed using Uviband 1D analysis software (UVItec Limited, Cambridge,
UK).
Statistical analysis
All data represent at least three independent experiments, expressed as the mean ± the stan-
dard deviation. Statistical comparisons were made by ANOVA followed by Turkey Multiple
Comparison Test. Analyses were performed with GraphPad Prism 4.0 software (GraphPad
Software Inc., San Diego, CA, USA). Values of p<0.05 were considered statistically significant.
Results
B-1 lymphocytes, but not the other peritoneal cell population, increase
the metastatic behavior of melanoma cells in an IL-10-dependent
manner
To prove the non-engagement of the peritoneal cells other than the B-1 lymphocytes in the pro-
metastatic effect on the B16F10 melanoma cells, we took advantage of the B cell-deficient
(BKO) C57/BL6 mice. The BKO mice are deficient in both the B-1 and the B-2 lymphocytes.
Briefly, total peritoneal cells were isolated from the wild-type (WT) or the BKO mice and were
cultured for 40 min followed by the removal of non-adherent cells. The WT adherent peritoneal
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cells (WTapc) were collected and co-cultured with the B16F10 melanoma cells at 10:1 ratio for
48 h. The mice which received B16F10 co-cultivated with WTapc exhibited more metastatic
nodules than the ones which were injected with B16F10 cells, either cultivated alone or with the
BKO mice adherent peritoneal cells (BKOapc, Fig 1A). To further confirm that B-1 lymphocytes
are responsible for the aggressiveness of the tumor, B16F10 melanoma cells were co-cultivated
with purified peritoneal B-1 lymphocytes (CD19+CD23-; S1 Fig) or the non-B-1 peritoneal cells.
As depicted in the Fig 1B, only the purified B-1 lymphocytes (B16+pB-1) enhanced the meta-
static potential of the B16F10 melanoma cells.
Endogenous IL-10 drives the pro-metastatic effect of B-1 lymphocytes
on B16F10 melanoma cells
Although earlier studies have reported that the addition of exogenous IL-10 to melanoma cul-
tures has no effect on the B16F10 behavior [6], we hypothesized that endogenous IL-10 could
influence the metabolism of B-1 lymphocytes; thereby indirectly affecting the B16F10 meta-
static potential. To test this, we checked by flow cytometry analysis phenotypic differences
between B-1 lymphocytes from WT and IL-10-/- mice. Fig 2A illustrates that there was no sig-
nificant difference, neither in the phenotype nor in the total number of cells that were recov-
ered after the culture of peritoneal cells from the WT or the IL-10-/- mice. In contrast, the
animals that were inoculated with the B16F10 cells co-cultured with B-1WT lymphocytes pre-
sented a higher number of lung melanoma colonies in comparison to the mice that received
B16F10 cells cultivated alone or co-cultured with the B-1IL-10-/- lymphocytes (Fig 2B). Conse-
quently, such data supported the notion that the influence of B-1 lymphocytes in the behavior
of melanoma cells depends upon the endogenous IL-10 levels.
IL-10 deficiency impairs the expression of claudin-10 in B-1 lymphocytes
Since the flow cytometry analysis did not reveal any phenotypic differences between the B-
1WT and the B-1IL-10-/- cells (Fig 2A), we used the high throughput microarray technique to
obtain the gene expression profiles of these cells. The comparison analyses were done using
the MEV software, and the statistically significant transcripts were selected by the unpaired
two-class SAM analysis (FDR and Q-value 4%) by applying 500 random permutations. Using
these parameters, the chip analysis revealed the variations in the expression of eleven (11)
genes between the WT and the IL10-/- B-1 lymphocytes (Fig 3A). The analysis of the regulated
gene clusters by the DAVID Functional Annotation Chart tool displayed relevant differences
between the WT and the IL-10-/- B-1 lymphocytes in a group of five genes: three up-regulated
(cldn-10, mid-1, ldlrap1) and two down-regulated (cnr2 and nnt). Among these five (5) genes,
we validated the expression of claudin-10 (cldn-10) transcript because the claudin family of
proteins has been associated, either positively or negatively, with the progression of various
tumors [13–16]. In accordance with the microarray results, the western blot analysis also
showed the down-regulation of claudin-10 in the B-1IL-10-/- lymphocytes as compared to the
B-1WT cells (Fig 3B).
Claudin-10 mediates the interplay between B-1 lymphocytes and
melanoma cells
In an attempt to verify the role of claudin-10 gene in our model, we used the Stealth RNAiTM
siRNA technology. The B-1WT lymphocytes were transfected with claudin-10 siRNA1,
siRNA2 or siRNA3 sequences and subjected to western blotting to verify the abrogation of
transcription of the claudin-10 gene. Among the three siRNAs, only the siRNA1 exhibited
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significant inhibition of the claudin-10 gene expression in B-1 cells (Fig 4A). To determine the
role of claudin-10 in the pro-metastatic effect of B-1 lymphocytes, the B16F10 cells were co-
cultured for 48 h with B-1 lymphocytes, untransfected or transfected, with claudin-10 siRNAs
followed by experimental metastasis assay. The inhibition of claudin-10 expression by siRNA1
Fig 1. B-1 lymphocytes, but not other peritoneal cells, induce the pro-metastatic effect on B16F10
melanoma cells. A) Adherent peritoneal cells (apc) from wild-type mice, but not from B cell-deficient mice
(BKO), obtained from enriched peritoneal cell cultures increases B16F10 metastatic potential upon cell-to-cell
contact. B) The same results were obtained with cell-sorting technique, confirming that B-1 lymphocytes are
responsible for changes in the melanoma behavior. (Bars represent the mean number of lung tumor per
experimental condition ±SD (n = 4); **p < 0.01; ***p < 0.001, using one-way ANOVA with Tukey’s post hoc
test.
https://doi.org/10.1371/journal.pone.0187333.g001
Fig 2. Endogenous IL-10 drives the influence of B-1 lymphocytes in B16F10 behavior. A) The
deficiency in IL-10 production did not affect the phenotype and the number of B-1 lymphocytes recovered from
the culture of peritoneal cavity cells; B) but affected their ability to increase the metastatic potential of B16F10
melanoma cells. Bars represent the mean number of lung colonies per experimental condition ±SD.
**p <0.001, using one-way ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0187333.g002
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impaired the B-1 lymphocyte mediated increase of the metastatic potential of B16F10 cells (Fig
4B). In contrast, the mice, which were inoculated with the B16F10 cells co-cultured with the
siRNA2 or siRNA3 transfected or untransfected B1 cells, demonstrated the highest number of
lung melanoma metastases (Fig 4B). In addition, the suppression of the claudin-10 expression
in B-1 lymphocytes inhibited the ERK pathway activation in B16F10 cells post contact with B-
1 lymphocytes (Fig 4C). Similarly, increase in claudin-10 expression in the B16F10 cells upon
contact with B-1 lymphocytes was also inhibited, indicating that the ERK pathway is involved
in the expression of claudin-10 in the melanoma cells. Of note, B-1 lymphocytes that were co-
transfected with the negative control siRNA displayed the expression of claudin-10 gene and
the pro-metastatic influence on the B16F10 cells (S2 Fig). This finding signified that only the
claudin-10 gene silencing specifically led to the observed phenomenon.
Finally, to further confirm the role of claudin-10 in bringing out the changes that are observed
in the melanoma cells after contact with B-1 lymphocytes, the claudin-10 expression was inhib-
ited in the B16F10 cells. As hypothesized, in the absence of claudin-10, B-1 lymphocytes were
Fig 3. IL-10 deficiency is associated with impaired expression of claudin-10 in B-1 lymphocytes. Total
RNA of B-1 lymphocytes enriched culture from wild-type (B-1WT) or IL-10-/- knockout (B-1IL-10-/-) mice was
submitted to microarray analysis. A) Heatmap showing differential expression of eleven transcripts between
B-1WT and B-1IL-10-/- lymphocytes, and the down-regulation of claudin-10 (cldn-10) in B-1IL-10-/- samples.
B) Western blot analysis of cldn-10 protein in whole-cell extracts from B-1WT and B-1IL-10-/-. β-actin protein
was used as internal control.
https://doi.org/10.1371/journal.pone.0187333.g003
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unable to modulate the metastatic behavior of the B16F10 melanoma cells (Fig 5). Thus, our
findings demonstrate that claudin-10 is a key mediator in the interplay between B-1 lymphocytes
and B16F10 melanoma cells and is involved in the enhancement of melanoma aggressiveness
upon contact with the B-1 cells.
Discussion
Like the other cells of the immune system, B-1 lymphocytes can be associated with protective
or deleterious responses depending on the context in which they are activated [3, 4, 17–19].
Fig 4. Claudin-10 expression on B-1 lymphocytes mediates the alterations in B16F10 melanoma cell
behavior. A) Expression of claudin-10 on B-1 lymphocytes from peritoneal cell culture transfected for 24 h
with stealth claudin-10 siRNA1 (B-1 cldn-10 siRNA1), siRNA2 (B-1 cldn-10 siRNA2), siRNA3 (B-1 cldn-10
siRNA3). B) The number of lung colonies in mice injected with B16F10 melanoma cells from single culture
(B16F10) or after co-cultivation with B-1 lymphocytes (B16F10+B1), transfected or not with claudin-10
siRNA1 (B16F10 + B-1 cldn-10siRNA1), siRNA2 (B16F10 + B-1 cldn-10 siRNA2), siRNA3 (B16F10 + B-1
cldn-10 siRNA3). C) Inhibition of claudin-10 expression impairs the activation of ERK pathway and the
claudin-10 expression in B16F10 cells after B-1 contact. GAPDH was used as internal control. Bars represent
the mean number of lung colonies per experimental condition ±SD. *p < 0.05; **p < 0.01;***p < 0.001, using
one-way ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0187333.g004
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Concerning the involvement of B-1 lymphocytes in tumor behavior, we found that analogous
to tumor-associated macrophages (TAMs), the B-1 lymphocytes seem to promote growth and
spread of melanoma cells [5, 6, 20, 21]. Previously, we reported that the pro-metastatic effect of
B-1 lymphocytes on the B16F10 melanoma cells was dependent upon the cell-to-cell contact
and the ERK signaling, however, the mechanisms involved in this phenomenon remained
unclear [5, 6, 9]. Since IL-10 is known to play an important role in B-1 biology, we hypothe-
sized that the cytokine could be involved in the behavior alteration that is observed in the case
of the B16F10 melanoma cells.
In the present study, we demonstrated that the peritoneal cells other than the B-1 lymphocytes
were not able to boost the melanoma aggressiveness. Although a previous study demonstrated
Fig 5. Inhibition of claudin-10 expression in B16F10 inhibits the influence of B-1 lymphocytes in
melanoma aggressiveness. B16F10 cells were transfected for 24h with stealth claudin-10 siRNA1. The
inhibition of claudin-10 expression in B16F10 blocks A) activation of ERK pathway and claudin-10 expression
and, B) impairs the B16F10 aggressiveness induced by the contact with B-1 lymphocytes. (Bars represent the
mean number of lung tumor per experimental condition ±SD (n = 3). **p < 0.01; ***p < 0.001, using one-way
ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0187333.g005
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that IL-10, itself, was unable to modulate the B16F10 behavior, its influence on the cross-talk
between the B-1 lymphocytes and the melanoma cells was not clear [6]. Thus, we co-cultured the
B16F10 cells with B-1 lymphocytes that were isolated from IL-10-/- mice. The IL-10-deficient B-1
lymphocytes were unable to induce alterations in the metastatic melanoma behavior, indicating
that the IL-10 production by B-1 lymphocytes plays a pivotal role in the interplay between these
cells.
Furthermore, in an attempt to investigate the influence of IL-10 in B-1 cell biology, we eval-
uated the effect of IL-10 in gene expression profile of the B-1 lymphocytes. The microarray
analysis revealed differential expression of eleven (11) transcripts among the B-1WT and B-
1IL-10-/- lymphocytes, which was in concordance with the hypothesis that the endogenous IL-
10 plays crucial role in the B-1 physiology. Among the 11 transcripts, claudin-10 was downre-
gulated in the IL-10-/- B-1 lymphocytes and seemed to be the most important mediator in the
BF16/B-1 interaction. Firstly, the claudin family of proteins presents the major integral pro-
teins that constitute the backbone of tight junctions, being involved in cell-to-cell contact [22]
and; secondly, the claudin gene expression may be regulated by the ERK signaling pathway [6,
23], which is up-regulated in both the B16F10 cells and the B-1 lymphocytes after contact with
each other [6, 23].
To determine the influence of claudin-10 in the interaction between the B-1-lymphocytes
and the melanoma cells, claudin-10 expression was inhibited using RNAi approach. The sup-
pression of claudin-10 levels in the B-1 lymphocytes impaired the ability of the latter to
increase the aggressiveness of melanoma cells, which was accomplished by the down-modula-
tion of the ERK signaling pathway (Fig 4C). Thus data from the present work corroborated the
previous findings that established an association between the ERK signaling and the tumor
aggressiveness [6] and, supporting the notion that claudin-10 is involved in the changes in
melanoma cells upon contact with B-1 lymphocytes. In addition, similar results were recorded
when claudin-10 was inhibited in the B16F10 cells, validating the role of claudin-10 as a media-
tor to increase the metastatic potential of B16F10 melanoma after contact with B-1 lympho-
cytes. Together, these data support the hypothesis that homotypic interactions mediated by
claudin-10 are required to trigger the more metastatic behavior on B16F10 melanoma cells
after contact with B-1 lymphocytes.
Conclusions
In summary, our findings demonstrate that endogenous IL-10 influences the expression of
claudin-10 in B-1 lymphocytes and implicate the axis IL-10/claudin-10 to augment the aggres-
sive behavior of the B16F10 melanoma cells upon contact with B-1 lymphocytes. Thus, the
identification of claudin-10 as a mediator of the pro-metastatic effect of B-1 lymphocytes on
melanoma cells reveals a potential target for the development of molecular therapeutics to con-
trol the melanoma metastasis.
Supporting information
S1 Fig. Gate strategy for B-1 lymphocyte purification by flow cytometry after cell culture.
The gate strategy resulted in single cells with purity of> 99.5% after electronic cell sorting.
(TIFF)
S2 Fig. The siRNA methodology has no effect on B1-lymphocyte ability to promote
B16F10 aggressiveness. B-1 lymphocytes were transfected for 24 h with claudin-10 siRNA or
negative siRNA to determine the impact of stealth methodology in their activity on B16F10
cells. A) The inhibition of claudin-10 expression depends on the specific siRNA used. B) The
Claudin-10 is involved in the pro-metastatic effect of B-1 lymphocytes on B16F10 melanoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0187333 November 16, 2017 11 / 13
negative stealth siRNAi has no effect on B-1 lymphocytes’ ability to promote further the meta-
static behavior in B16F10 melanoma cells. Data are the mean ± SD of three independent exper-
iments. p< 0.0001, using one-way ANOVA with Tukey’s post hoc test.
(TIFF)
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